Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study (Q85303251)
Jump to navigation
Jump to search
scientific article published on 18 January 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study |
scientific article published on 18 January 2013 |
Statements
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study (English)
R G Langley
M Abe
D R Baker
P Konno
S Haemmerle
H J Thurston
C Papavassilis
H B Richards
18 January 2013